KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Idexx Laboratories (IDXX) Shares Outstanding (2016 - 2026)

Idexx Laboratories has reported Shares Outstanding over the past 17 years, most recently at $108.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding changed 0.49% year-over-year to $108.4 million; the TTM value through Dec 2025 reached $108.4 million, changed 0.49%, while the annual FY2025 figure was $108.4 million, 0.49% changed from the prior year.
  • Shares Outstanding for Q4 2025 was $108.4 million at Idexx Laboratories, up from $80.0 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $108.4 million in Q4 2025 and troughed at $80.0 million in Q3 2025.
  • A 5-year average of $106.0 million and a median of $107.3 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: increased 0.72% in 2021 and later decreased 25.72% in 2025.
  • Year by year, Shares Outstanding stood at $106.9 million in 2021, then increased by 0.29% to $107.2 million in 2022, then increased by 0.29% to $107.5 million in 2023, then rose by 0.31% to $107.8 million in 2024, then rose by 0.49% to $108.4 million in 2025.
  • Business Quant data shows Shares Outstanding for IDXX at $108.4 million in Q4 2025, $80.0 million in Q3 2025, and $108.0 million in Q2 2025.